EP Patent

EP3654952A1 — Pharmaceutical compositions comprising entrectinib

Assigned to Ignyta Inc · Expires 2020-05-27 · 6y expired

What this patent protects

The present invention relates to pharmaceutical compositions and dosage forms comprising N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (4-methylpiperazin-1-yl) -2 - (tetrahydro-2H-pyran-4-ylamino) benzamide which are useful in the treatment of subjects suffering from cancer. …

USPTO Abstract

The present invention relates to pharmaceutical compositions and dosage forms comprising N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (4-methylpiperazin-1-yl) -2 - (tetrahydro-2H-pyran-4-ylamino) benzamide which are useful in the treatment of subjects suffering from cancer. The present invention also relates to methods of making such pharmaceutical compositions and dosage forms, and methods of treating subjects with cancer using the pharmaceutical compositions and dosage forms described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3654952A1
Jurisdiction
EP
Classification
—
Expires
2020-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.